Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Hum Exp Toxicol ; 40(2): 297-309, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32812462

RESUMEN

In this study, both diabetes and Dunning prostate cancer were induced for the first time in Copenhagen rats in vivo. Thus, the effects of metformin against heart tissue damage of these rats were investigated by biochemical methods. Dunning prostate cancer was induced in Copenhagen rats using high metastatic MAT-LyLu cells. The rats were divided as follows: Control group: only injected with 0.9% NaCl for 14 days; Diabetic group: only injected single dose of streptozotocin (STZ) (65 mg/kg); Cancer group: subcutaneously (s.c) inoculated with 2 x 104 MAT-LyLu cells only; Diabetic + cancer (DC) group: inoculated with 2 x 104 MAT-LyLu cells and STZ injection, Cancer + metformin (CM) group: injected with metformin for 14 days after Mat-LyLu cells application; Diabetic + cancer + metformin (DCM) group: metformin administered for 14 days together with STZ and Mat-LyLu cells. At the end of the experimental period, heart tissues were taken. Reduced glutathione and total antioxidant status levels in heart tissues were decreased, whereas lipid peroxidation, advanced oxidized protein products, nitric oxide, homocysteine, and reactive oxygen species levels, total oxidant status and catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and xanthine oxidase activities increased in the diabetic, cancer and DC groups. Treatment with metformin reversed these effects. In conclusion, the present study shows that metformin has a protective effect against heart tissue damage in STZ-induced diabetic rats with Dunning prostate cancer.


Asunto(s)
Antiinflamatorios/uso terapéutico , Antineoplásicos/uso terapéutico , Antioxidantes/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Lesiones Cardíacas/tratamiento farmacológico , Metformina/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Animales , Antiinflamatorios/farmacología , Antineoplásicos/farmacología , Antioxidantes/farmacología , Línea Celular Tumoral , Diabetes Mellitus Experimental/metabolismo , Glutatión/metabolismo , Lesiones Cardíacas/metabolismo , Homocisteína/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Masculino , Metformina/farmacología , Miocardio/metabolismo , Óxido Nítrico/metabolismo , Oxidorreductasas/metabolismo , Neoplasias de la Próstata/metabolismo , Ratas , Especies Reactivas de Oxígeno/metabolismo
2.
Hum Exp Toxicol ; 39(4): 423-432, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31789064

RESUMEN

Galectin-1 is an important mediator that regulates the T-cell-mediated immune response. It has many other biological functions such as cell growth, immunomodulation, and wound healing. The aim of this study was to reveal the role of galectin-1 on liver morphology, cell proliferation, apoptosis, inflammatory and anti-inflammatory mediators, oxidative stress, and antioxidant system in colitis-mediated hepatotoxicity induced by dextran sulfate sodium (DSS). In the present study, adult mice were divided into four groups: The control group intraperitoneally injected with phosphate buffer saline (I), the group which was orally administered with DSS (II), the control group which was injected with galectin-1 (III), and the group which was given DSS and galectin-1 (IV). DSS administration caused degenerative changes and diffuse necrotic damage, an increase in caspase-3 and cyclooxygenase-2 expression, the levels of lipid peroxidation and tumor necrosis factor-alpha, lactate dehydrogenase, and myeloperoxidase activities, and a decrease in cell proliferation, interleukin-10 levels, and antioxidant system parameters in liver tissues. Treatment of DSS group with galectin-1 reversed these effects and prevented liver damage. This study showed that galectin-1 has proliferative, antiapoptotic, anti-inflammatory, and antioxidant effects against DSS-induced liver injury in mice. It is expected considering all results of this study that galectin-1 may be useful as a protective agent against liver toxicity.


Asunto(s)
Apoptosis/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Galectina 1/farmacología , Hígado/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/farmacología , Animales , Apoptosis/inmunología , Caspasa 3/genética , Proliferación Celular/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/enzimología , Enfermedad Hepática Inducida por Sustancias y Drogas/inmunología , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Colitis Ulcerosa/complicaciones , Ciclooxigenasa 2/genética , Citocinas/metabolismo , Sulfato de Dextran/toxicidad , Modelos Animales de Enfermedad , Inyecciones Intraperitoneales , Hígado/enzimología , Hígado/patología , Ratones Endogámicos C57BL , Estrés Oxidativo/genética , Estrés Oxidativo/inmunología , Proteínas Recombinantes/farmacología
3.
Hum Exp Toxicol ; 24(3): 129-35, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15901052

RESUMEN

Metformin is a biguanide derivate used as an oral hypoglycaemic drug in diabetics. The aim of this study was to examine the histological and biochemical effects of metformin in streptozotocin (STZ)-treated rats. The animals were rendered diabetic by intraperitoneal injection of 65 mg/kg STZ. Fourteen days later, metformin was given at 25 mg/kg by gavage, daily for 28 days, to STZ-diabetic rats and a control group. In the STZ-diabetic group, some degenerative changes were observed by light microscopic examination. But the degenerative changes were decreased in the STZ-diabetic group given metformin. In the STZ-diabetic group, blood glucose levels, serum alanine and aspartate transaminase (ALT and AST) activities, total lipid levels, and sodium and potassium levels increased, while body weight, serum magnesium levels and liver glutathione (GSH) levels decreased. In the STZ-diabetic group given metformin, blood glucose levels, serum ALT and AST activities, total lipid, and sodium and potassium levels decreased, and liver GSH and serum magnesium levels increased. As a result of all the morphological and biochemical findings obtained, it was concluded that metformin has a protective effect against the hepatotoxicity produced by STZ diabetes.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Hígado , Metformina/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Animales , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Femenino , Hipoglucemiantes/administración & dosificación , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Pruebas de Función Hepática , Metformina/administración & dosificación , Sustancias Protectoras/administración & dosificación , Ratas
4.
Hum Exp Toxicol ; 23(5): 257-64, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15228018

RESUMEN

Glibornuride is a sulphonylurea derivative used as an oral hypoglycaemic drug in diabetics. The aim of this study was to examine the histological, ultrastructural and biochemical effects of glibornuride in streptozotocin (STZ)-treated rats. The animals were rendered diabetic by intraperitoneal injection of 65 mg/kg STZ. Fourteen days later, glibornuride was given at 5 mg/kg by gavage, daily for 28 days, to one STZ-diabetic and one control group. In the STZ-diabetic group, remarkable degenerative changes were observed. On the other hand, in the STZ-diabetic group given glibornuride, the degenerative changes decreased. In the STZ-diabetic group, blood glucose levels, serum aspartate transaminase activity, and total lipid levels increased, whereas the blood glutathione levels decreased. In contrast, in the STZ-diabetic group given glibornuride blood glucose levels, serum aspartate transaminase activity and total lipid levels decreased and blood glutathione levels increased. Significant changes in total protein levels in the serum were not observed in any group. As a conclusion, we can say that glibornuride has a protective effect against the hepatotoxicity produced by STZ-diabetes.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/farmacología , Hepatopatías/prevención & control , Hígado/efectos de los fármacos , Compuestos de Sulfonilurea/farmacología , Administración Oral , Animales , Aspartato Aminotransferasas/sangre , Glucemia/análisis , Enfermedad Hepática Inducida por Sustancias y Drogas , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/patología , Modelos Animales de Enfermedad , Femenino , Glutatión/sangre , Hepatocitos/efectos de los fármacos , Hepatocitos/ultraestructura , Hipoglucemiantes/administración & dosificación , Lípidos/sangre , Hígado/patología , Hepatopatías/patología , Microscopía Electrónica de Transmisión , Ratas , Ratas Endogámicas , Compuestos de Sulfonilurea/administración & dosificación
5.
Phytother Res ; 18(12): 996-9, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15742348

RESUMEN

Parsley is used by diabetics in Turkey to reduce blood glucose. The present study aims to investigate both the morphological and biochemical effects of parsley on liver tissue. Rat hepatocytes were examined by light and electron microscopy. Degenerative changes were observed in the hepatocytes of diabetic rats. These degenerative changes were significantly reduced or absent in the hepatocytes of diabetic rats treated with parsley. Blood glucose levels, alanine transaminase and alkaline phosphatase were observed to be raised in diabetic rats. Diabetic rats treated with parsley demonstrated significantly lower levels of blood glucose, alanine transaminase and alkaline phosphatase. The present study suggests that parsley demonstrates a significant hepatoprotective effect in diabetic rats.


Asunto(s)
Hipoglucemiantes/farmacología , Hígado/efectos de los fármacos , Petroselinum , Fitoterapia , Extractos Vegetales/farmacología , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Animales , Glucemia , Diabetes Mellitus Experimental/prevención & control , Hepatocitos/efectos de los fármacos , Hepatocitos/ultraestructura , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Hígado/enzimología , Hígado/patología , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Ratas
6.
Phytother Res ; 16(8): 758-61, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12458482

RESUMEN

The aim of this work was to investigate the effects of chard (Beta vulgaris L. var. cicla) extract on serum urea and creatinine concentrations and on kidney tissue in normal and streptozotocin-diabetic rats. The extract was administered to rats at a dose of 2 g/kg every day for 28 days, 14 days after animals were made diabetic. On day 42, kidney tissue and blood samples were examined. Significant degenerative changes in kidney tissue of diabetic rats were observed, but in the group given chard extract, the morphology of kidney tissue was found to be nearly the same as the controls. Serum urea and creatinine levels significantly increased in the diabetic groups, but the chard extracts significantly reduced serum urea and creatinine levels. It is concluded that the extract of this plant may reduce serum urea and creatinine levels and confer a protective effect on the kidney of diabetic rats.


Asunto(s)
Beta vulgaris , Hipoglucemiantes/farmacología , Riñón/efectos de los fármacos , Fitoterapia , Extractos Vegetales/farmacología , Administración Oral , Animales , Creatinina/sangre , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Riñón/patología , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Hojas de la Planta , Distribución Aleatoria , Ratas , Estreptozocina , Urea/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...